Novartis Gene Therapies, Inc. drugs

1 result
  • zolgensma - onasemnogene abeparvovec - xioi

    (Onasemnogene Abeparvovec-Xioi)
    Novartis Gene Therapies, Inc.
    Zolgensma is a gene therapy for pediatric patients under 2 years old with spinal muscular atrophy (SMA) caused by bi-allelic mutations in the SMN1 gene.